Mergers & Acquisitions ·
MaxCyte agrees to acquire Akron Bio for $151.8M in cash and stock
MXCTMaxcyte, Inc.
MaxCyte has entered into a definitive agreement to acquire Akron BioProducts LLC from affiliates of Arcline Investment Management for total consideration of approximately $151.8 million. The deal consists of $105.0 million in upfront cash, 20,639,733 shares of MaxCyte common stock valued at roughly $26.8 million based on the November 9 closing price, and $20.0 million in guaranteed deferred payments split between January 2028 and January 2029. The transaction is expected to close before the end of 2026, subject to customary conditions including Hart-Scott-Rodino approval and Nasdaq listing for the stock consideration, but does not require financing or shareholder approval. MaxCyte has also secured a $75.0 million credit facility with MidCap Financial to support the acquisition and operations. MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics.